Townsend G C, Scheld W M
Department of Internal Medicine, University of Virginia, Charlottesville 22908, USA.
J Antimicrob Chemother. 1996 Jun;37(6):1051-61. doi: 10.1093/jac/37.6.1051.
Despite the introduction of newer antimicrobial agents, bacterial meningitis continues to be associated with significant morbidity and mortality. Evidence from in-vitro studies, experimental animal models, and clinical studies indicate that the host inflammatory response is responsible for much of the deleterious consequences of this disease. Thus, there is much interest in the adjunctive use of antiinflammatory agents in the therapy of bacterial meningitis. Although there is considerable evidence from animal models and from clinical trials in children that adjunctive antiinflammatory therapy with corticosteroids is effective in reducing inflammation and in improving long-term outcomes, similar data involving adults are largely lacking. The rationale for the use of corticosteroids in the management of bacterial meningitis, and the applicability to disease in adults, are discussed, and some recommendations for their use in this setting are made.
尽管引入了更新的抗菌药物,但细菌性脑膜炎仍然与显著的发病率和死亡率相关。体外研究、实验动物模型和临床研究的证据表明,宿主炎症反应是该疾病许多有害后果的原因。因此,人们对在细菌性脑膜炎治疗中辅助使用抗炎药物非常感兴趣。虽然动物模型和儿童临床试验有大量证据表明,使用皮质类固醇进行辅助抗炎治疗可有效减轻炎症并改善长期预后,但涉及成人的类似数据却基本缺乏。本文讨论了在细菌性脑膜炎管理中使用皮质类固醇的基本原理及其对成人疾病的适用性,并给出了在这种情况下使用皮质类固醇的一些建议。